REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy.

Title

REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy.

Authors

Keywords

-

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 31, Issue 4_suppl, Pages LBA5-LBA5

Publisher

American Society of Clinical Oncology (ASCO)

Online

2017-02-24

DOI

10.1200/jco.2013.31.4_suppl.lba5